Estudio del papel modulador de la proteína Quinasa C y la Aurora Quinasa sobre las líneas celulares HMC-1560 y HMC-1560,816

Los resultados obtenidos demuestran la importancia que posee la proteína quinasa C (PKC) en el proceso de activación de la líneas de mastocitos HMC-1560 y HMC-1560,816, presentes en pacientes con mastocitosis. La trascendencia de esta proteína se pone también de manifiesto al ser imprescindible en el tratamiento con inhibidores de tirosina quinasas, considerado el grupo de mayor relevancia en el tratamiento de las mastocitosis. Además, la activación de la PKC durante un periodo de tiempo prolongado provoca apoptosis en ambas líneas celulares y la modulación de ambas proteínas, PKC y tirosina quinasas, tiene como resultado una potenciación del efecto citotóxico de este último grupo y por tanto mayor eficacia anticancerígena. Finalmente se ha estudiado la aurora quinasa, otra de las proteínas implicadas en el proceso de proliferación celular. La inhibición de esta proteína con el compuesto CCT129202 causa apoptosis dependiente de la PKC. Por lo tanto, la presente tesis doctoral ha permitido determinar el papel modulador de la PKC sobre diversos compuestos anticancerígenos, esclareciendo su mecanismo de acción con el fin de alcanzar la mayor eficacia en el tratamiento

Yessotoxin, a Marine Toxin, Exhibits AntiAllergic and Anti-Tumoural Activities Inhibiting Melanoma Tumour Growth in a Preclinical Model

Yessotoxins (YTXs) are a group of marine toxins produced by the dinoflagellates Protoceratium reticulatum, Lingulodinium polyedrum and Gonyaulax spinifera. They may have medical interest due to their potential role as anti-allergic but also anti-cancer compounds. However, their biological activities remain poorly characterized. Here, we show that the small molecular compound YTX causes a slight but significant reduction of the ability of mast cells to degranulate. Strikingly, further examination revealed that YTX had a marked and selective cytotoxicity for the RBL-2H3 mast cell line inducing apoptosis, while primary bone marrow derived mast cells were highly resistant. In addition, YTX exhibited strong cytotoxicity against the human B-chronic lymphocytic leukaemia cell line MEC1 and the murine melanoma cell line B16F10. To analyse the potential role of YTX as an anti-cancer drug in vivo we used the well-established B16F10 melanoma preclinical mouse model. Our results demonstrate that a few local application of YTX around established tumours dramatically diminished tumour growth in the absence of any significant toxicity as determined by the absence of weight loss and haematological alterations. Our data support that YTX may have a minor role as an anti-allergic drug, but reveals an important potential for its use as an anti-cancer drugDr. Araceli Tobio Ageitos was supported by a postdoctoral fellowship from Fundación Juana de Vega, Spain. Dr. Iris Madera-Salcedo was supported by an International collaboration grant between ANR France (ANR-12-ISV3-0006-01) and Conacyt Mexico (Conacyt-ANR 188565). This research project has been supported by the Investissements d’Avenir programme ANR-11-IDEX-0005-02, Sorbonne Paris Cite, Laboratoire d’excellence INFLAMEX, and DHU Fire. This work was also supported by the COST Action BM1007 (Mast cells and basophils–targets for innovative therapies) of the European CommunityS

Surface Plasmon Resonance Biosensor Method for Palytoxin Detection Based on Na+,K+-ATPase Affinity

Palytoxin (PLTX), produced by dinoflagellates from the genus Ostreopsis was first discovered, isolated, and purified from zoanthids belonging to the genus Palythoa. The detection of this toxin in contaminated shellfish is essential for human health preservation. A broad range of studies indicate that mammalian Na+,K+-ATPase is a high affinity cellular receptor for PLTX. The toxin converts the pump into an open channel that stimulates sodium influx and potassium efflux. In this work we develop a detection method for PLTX based on its binding to the Na+,K+-ATPase. The method was developed by using the phenomenon of surface plasmon resonance (SPR) to monitor biomolecular reactions. This technique does not require any labeling of components. The interaction of PLTX over immobilized Na+,K+-ATPase is quantified by injecting different concentrations of toxin in the biosensor and checking the binding rate constant (kobs). From the representation of kobs versus PLTX concentration, the kinetic equilibrium dissociation constant (KD) for the PLTX-Na+,K+-ATPase association can be calculated. The value of this constant is KD = 6.38 × 10−7 ± 6.67 × 10−8 M PLTX. In this way the PLTX-Na+,K+-ATPase association was used as a suitable method for determination of the toxin concentration in a sample. This method represents a new and useful approach to easily detect the presence of PLTX-like compounds in marine products using the mechanism of action of these toxins and in this way reduce the use of other more expensive and animal based methods.The research leading to these results has received funding from the following FEDER cofunded-grants: From Ministerio de Ciencia y Tecnología, Spain: AGL2009-13581-CO2-01, AGL2012-40485-CO2-01. From Xunta de Galicia, Spain: 10PXIB261254 PR. From the European Union’s Seventh Framework Programme managed by REA—Research Executive Agency http://ec.europa.eu/research/rea (FP7/2007–2013) under grant agreement Nos. 211326-CP (CONffIDENCE), 265896 BAMMBO, 265409 µAQUA, and 262649 BEADS, 315285 Ciguatools and 312184 PharmaSea. From the Atlantic Area Programme (Interreg IVB Trans-national): 2008-1/003 (Atlantox) and 2009-1/117 (Pharmatlantic)S

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production

Persistent dysregulation of IL-6 production and signaling have been implicated in the pathology of various cancers. In systemic mastocytosis, increased serum levels of IL-6 associate with disease severity and progression, although the mechanisms involved are not well understood. Since systemic mastocytosis often associates with the presence in hematopoietic cells of a somatic gain-of-function variant in KIT, D816V-KIT, we examined its potential role in IL-6 upregulation. Bone marrow mononuclear cultures from patients with greater D816V allelic burden released increased amounts of IL-6 which correlated with the percentage of mast cells in the cultures. Intracellular IL-6 staining by flow cytometry and immunofluorescence was primarily associated with mast cells and suggested a higher percentage of IL-6 positive mast cells in patients with higher D816V allelic burden. Furthermore, mast cell lines expressing D816V-KIT, but not those expressing normal KIT or other KIT variants, produced constitutively high IL-6 amounts at the message and protein levels. We further demonstrate that aberrant KIT activity and signaling are critical for the induction of IL-6 and involve STAT5 and PI3K pathways but not STAT3 or STAT4. Activation of STAT5A and STATB downstream of D816V-KIT was mediated by JAK2 but also by MEK/ERK1/2, which not only promoted STAT5 phosphorylation but also its long-term transcription. Our study thus supports a role for mast cells and D816V-KIT activity in IL-6 dysregulation in mastocytosis and provides insights into the intracellular mechanisms. The findings contribute to a better understanding of the physiopathology of mastocytosis and suggest the importance of therapeutic targeting of these pathwaysThis work was supported by the Division of Intramural Research within the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.S

Yessotoxin, a Marine Toxin, Exhibits Anti-Allergic and Anti-Tumoural Activities Inhibiting Melanoma Tumour Growth in a Preclinical Model.

Yessotoxins (YTXs) are a group of marine toxins produced by the dinoflagellates Protoceratium reticulatum, Lingulodinium polyedrum and Gonyaulax spinifera. They may have medical interest due to their potential role as anti-allergic but also anti-cancer compounds. However, their biological activities remain poorly characterized. Here, we show that the small molecular compound YTX causes a slight but significant reduction of the ability of mast cells to degranulate. Strikingly, further examination revealed that YTX had a marked and selective cytotoxicity for the RBL-2H3 mast cell line inducing apoptosis, while primary bone marrow derived mast cells were highly resistant. In addition, YTX exhibited strong cytotoxicity against the human B-chronic lymphocytic leukaemia cell line MEC1 and the murine melanoma cell line B16F10. To analyse the potential role of YTX as an anti-cancer drug in vivo we used the well-established B16F10 melanoma preclinical mouse model. Our results demonstrate that a few local application of YTX around established tumours dramatically diminished tumour growth in the absence of any significant toxicity as determined by the absence of weight loss and haematological alterations. Our data support that YTX may have a minor role as an anti-allergic drug, but reveals an important potential for its use as an anti-cancer drug

Effect of YTX on MEC1 and B16F10 cell line viability.

<p>The MEC1 and B16F10 cell lines were incubated with 10, 30, 50 and 100nM YTX for the indicated times and cell viability was assessed by the MTT assay at the indicated time points. Corresponding controls with YTX solvent were performed and cell viability was arbitrarily set to 100%. Of note, solvent did not significantly affect cell viability as compared to non-treated cells even at the highest concentration of vehicle. Data are the mean ± SEM of three experiments. Significant differences between untreated and YTX-treated cells: (*) p≤0.05, (**) p≤0.01 and (***) p≤0.001.</p

YTX treatment decreases tumour development in the B16F10 melanoma mouse model.

<p>(A) Mice were injected subcutaneous B16F10 melanoma cells and tumours were allowed to develop until they reached a volume of 50 mm³ achieved between days 5 and 10. Mice were then either left untreated or were treated with the indicated concentrations of YTX or vehicle, which was injected subcutaneous right next to the tumour. (B) Representative glucose uptake after FX Pro Kodak image analysis of untreated, vehicle and YTX-treated mice at the day of sacrifice. (C) Corresponding resected tumour weight of animals after sacrifice at day 12 post-1st treatment. (D) Corresponding weight of untreated, vehicle- and YTX-treated mice. (E-G) Results of the haematological analysis performed before mice sacrifice. Data are expressed as mean ± SEM. Significant differences between untreated and YTX: (*) p≤0.05 and (***) p≤0.001.</p

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT

Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tissues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis are limited, thus exploration of novel pharmacological targets that reduce MC burden is desirable. Since increased generation of the lipid mediator sphingosine-1-phosphate (S1P) by sphingosine kinase (SPHK) has been linked to oncogenesis, we studied the involvement of the two SPHK isoforms (SPHK1 and SPHK2) in the regulation of neoplastic human MC growth. While SPHK2 inhibition prevented entry into the cell cycle in normal and neoplastic human MCs with minimal effect on cell survival, SPHK1 inhibition caused cell cycle arrest in G2/M and apoptosis, particularly in D816V-KIT MCs. This was mediated via activation of the DNA damage response (DDR) cascade, including phosphorylation of the checkpoint kinase 2 (CHK2), CHK2-mediated M-phase inducer phosphatase 3 depletion, and p53 activation. Combination treatment of SPHK inhibitors with KIT inhibitors showed greater growth inhibition of D816V-KIT MCs than either inhibitor alone. Furthermore, inhibition of SPHK isoforms reduced the number of malignant bone marrow MCs from patients with mastocytosis and the growth of D816V-KIT MCs in a xenograft mouse model. Our results reveal a role for SPHK isoforms in the regulation of growth and survival in normal and neoplastic MCs and suggest a regulatory function for SPHK1 in the DDR in MCs with KIT mutations. The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation

YTX treatment induced apoptosis in B16F10 cells.

<p>B16F10 cells were either left untreated or were treated for indicated times with 10, 30, 50 and 100nM YTX. YTX solvent controls were performed and no effects were observed. Cells were then analyzed for Annexin-V and PI staining by flow cytometry and the percentage of live cells (Annexin V-FITC -/PI -), early apoptotic (Annexin V-FITC +/PI -) and late apoptotic or necrotic cells (Annexin V-FITC +/PI +) was determined. Mean ± SEM of three experiments. Significant differences between untreated and YTX-treated cells: (*) p≤0.05, (**) p≤0.01 and (***) p≤0.001.</p